{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.2","upperLimit":"13.2","value":"7.8"},{"groupId":"OG001","lowerLimit":"8.7","upperLimit":"35.1","value":"15.9"},{"groupId":"OG002","lowerLimit":"5.2","upperLimit":"10.4","value":"6.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"30"}],"units":"Participants"}],"description":"DoR was defined as the time from date of first documented response of CR or PR to the date of first documented progressive disease (PD) or death due to any cause, whichever occurred earlier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received cemiplimab plus platinum-based doublet chemotherapy","id":"OG000","title":"Part 1: Cemiplimab + Chemotherapy"},{"description":"Participants received cemiplimab plus platinum-based doublet chemotherapy and ipilimumab","id":"OG001","title":"Part 1: Cemiplimab+AbbrevChemo+Ipilimumab"},{"description":"Participants received platinum-based doublet chemotherapy","id":"OG002","title":"Part 1: Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"Part 1 participants with confirmed CR or PR only. Overall number of participants analyzed = number of participants with evaluable data for the outcome measure","reportingStatus":"POSTED","timeFrame":"Up to 32 months","title":"Part 1: Duration of Response (DoR)","type":"SECONDARY","unitOfMeasure":"months"}